The finding of a stronger effect of APOE-e4 earlier in the disease progress might explain the observation of stronger genetic effect of APOE-e4 on Alzheimer’s disease in the group of 60- to 80-year-old people compared with people ≥80 years old.57-59 Given that amyloid deposition occurs 10+ years before other Alzheimer’s disease processes2 and APOE-e4 is the strongest common genetic risk factor for amyloid deposition, it would be expected for APOE-e4 to exert its maximum effect in younger people. This evidence concerns the gene APOE and amyloidosis.